Analytical Data
-
Gene name
HepaCAM2
- Application
-
Alternative Names
HepaCAM2;MIKI;HEPACAM family member 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A8MVW5
-
Expression Region
32-351aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSLKVTVPS HTVHGVRGQA LYLPVHYGFH TPASDIQIIW LFERPHTMPK YLLGSVNKSV VPDLEYQHKF TMMPPNASLL INPLQFPDEG NYIVKVNIQG NGTLSASQKI QVTVDDPVTK PVVQIHPPSG AVEYVGNMTL TCHVEGGTRL AYQWLKNGRP VHTSSTYSFS PQNNTLHIAP VTKEDIGNYS CLVRNPVSEM ESDIIMPIIY YGPYGLQVNS DKGLKVGEVF TVDLGEAILF DCSADSHPPN TYSWIRRTDN TTYIIKHGPR LEVASEKVAQ KTMDYVCCAY NNITGRQDET HFTVIITSVG LEKLAQKGKS LSP
-
Molecular Weight
38 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HepaCAM2, or Hepatic Cell Adhesion Molecule 2, is a member of the immunoglobulin superfamily known to play a critical role in cell adhesion and signaling in hepatic tissues. The study of HepaCAM2 is primarily motivated by its potential involvement in liver regeneration, tumor progression, and various liver diseases, including hepatocellular carcinoma. Research indicates that HepaCAM2 may help regulate cellular interactions within the liver microenvironment, influencing hepatocyte proliferation and migration. The understanding of HepaCAM2’s function is crucial for developing novel therapeutic strategies targeting liver pathologies. Recombinant protein expressing HepaCAM2 provides a valuable tool for investigating its biological functions and mechanisms. By creating pure, bioactive forms of this protein, researchers aim to elucidate its role in cell signaling pathways and its impact on liver cell dynamics. Additionally, studying HepaCAM2 may shed light on its potential as a biomarker for liver diseases and its applicability in regenerative medicine. Overall, the exploration of HepaCAM2 through recombinant protein technology holds promise for advancing our understanding of liver biology and developing innovative treatments for liver-related disorders.











